JNJ - Johnson & Johnson
| Previous close | 122.57 |
| Open | 122.42 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 800 |
| Day's range | 121.66 - 122.66 |
| 52-week range | 118.62 - 148.32 |
| Volume | 6,277,185 |
| Avg. volume | 6,659,493 |
| Market cap | 327.33B |
| Beta | 0.56 |
| PE ratio (TTM) | 270.00 |
| EPS (TTM) | 0.45 |
| Earnings date | 17 Jul 2018 |
| Forward dividend & yield | 3.60 (2.94%) |
| Ex-dividend date | 2018-05-25 |
| 1y target est | 144.45 |
- Market Realist•9 hours ago
How Johnson & Johnson’s Valuation Compares
Johnson & Johnson (JNJ), one of the world’s largest healthcare companies, has a diversified business spanning its consumer, medical device, and pharmaceutical segments. The company reported sales of $20 billion in Q1 2018 and adjusted EPS of $2.06. Let’s look at Johnson & Johnson’s valuation metrics.
Market Realist•11 hours agoA Look at Johnson & Johnson’s Stock Performance
Johnson & Johnson (JNJ) closed June 18 at $121.30 per share. The stock reached a 52-week low of $118.60 on May 29 as the company scrapped a Phase 1b/2 trial for its drug, Darzalex, for the treatment of advanced or metastatic non-small cell lung cancer patients, in combination with Roche’s (RHHBY) Tecentriq. Since then, the stock has risen ~1.6%.
- Market Realist•13 hours ago
What Analysts Recommend for Johnson & Johnson Stock
Johnson & Johnson (JNJ) is one of the biggest healthcare players in the world. However, it has been impacted by growing competition and pricing pressure in the industry in recent years and has revised its strategy. The company has witnessed recuperating sales in its medical devices business along with improving dynamics in its consumer business, which has encountered some litigation recently. The company’s pharmaceuticals business has performed steadily, with key trial data being announced. Let’s look at analysts’ recommendations for JNJ stock.
- Market Realist•15 hours ago
A Look at Allergan’s Valuation as of June 19
Allergan (AGN), a leading specialty pharmaceutical company, is focused on developing, manufacturing, and commercializing pharmaceutical and biologic products.
- Motley Fool•19 hours ago
Forget Johnson & Johnson: Here Are 2 Better Dividend Stocks
J&J's dividend is good. But these are even better.
Market Realist•yesterdayWhat’s the Latest on Teva’s Fremanezumab?
Teva’s (TEVA) much-awaited migraine drug, Fremanezumab, is in late-stage trials for the treatment of cluster headaches. The company provided an update regarding its Enforce Phase III clinical development program for the treatment of cluster headaches on June 15.
- Bloomberg•yesterday
Opioid Ruling Could Send Purdue, Drugmakers to Court
Purdue Pharma LP, Johnson & Johnson and other opioid makers faced one of the first extensive review of their legal defenses to state claims that they violated consumer-protection laws and created a public nuisance with the sale of the pain killers. New York state court Judge Jerry Garguilo on Monday rejected the pharma companies’ requests for the lawsuits be thrown out on a myriad of grounds, concluding lawyers for eight counties could move forward with their claims. While the ruling is based solely on New York law, it could provide a roadmap for other judges around the U.S. weighing whether states and local governments can proceed with claims that Purdue and other opioid makers understated the risks of prescription opioids and overstated their benefits.
- CNBC•2 days ago
There's one Dow stock having a great day — Verizon
Verizon was the only DJIA member trading significantly in the green on Tuesday. Deutsche Bank upgraded the wireless maker, saying shares were cheap.
- Motley Fool•2 days ago
3 Stocks That Are Absurdly Cheap Right Now
When stocks become nonsensically priced due to irrational market decisions, investors should act on the opportunity.
CNBC•2 days agoCramer floats idea for 'gloomy' ETF with Wall Street's most downtrodden stocks
Jim Cramer proposes starting a new exchange-traded fund with the stocks that scare investors most when trade tensions run high.
Associated Press•2 days agoMarkets Right Now: Stocks look to recover from early skid
NEW YORK (AP) — The latest on developments in financial markets (all times local):
- Reuters•3 days ago
After split from Actelion, Idorsia CEO plans to raise more cash in 2019
Swiss biotech Idorsia, spun off from Actelion last June with a $1 billion investment from buyer Johnson & Johnson, will seek fresh funding in 2019 to support late-stage trials of drugs getting underway, its CEO told Reuters. French founders Jean-Paul Clozel and his wife, Martine Clozel, sold Actelion for $30 billion last year, but only after extracting rights to 11 prized drugs in development, including an insomnia medicine nicknamed DORA. With 650 employees, Jean-Paul Clozel expects to burn through Idorsia's cash in about two years, before his drug hopefuls generate revenue - typical of the biotech industry where the risk of pipeline failures is ever-present but the rewards of striking paydirt, as was the case with Actelion, can be vast.
- Motley Fool•3 days ago
Why Geron Corporation Stock Is Heading Higher Today
The company's EHA conference over the weekend has investors snapping up shares today.
- Motley Fool•4 days ago
Big Pharma Stock Investors Beware: Another $250 Billion Patent Cliff Is Coming
Several big pharma companies are about to lose patent exclusivity for blockbuster drugs. Should investors be worried?
- Motley Fool•4 days ago
Better Buy: Johnson & Johnson vs. Eli Lilly
Which of these big pharma stocks has a better chance to outperform for your portfolio.
- Motley Fool•4 days ago
Better Buy: Pfizer Inc. vs. Johnson & Johnson
How do these two big pharma stocks compare in a head-to-head match?
- Barrons.com•5 days ago
[$$] Can Investment Performance Be Predicted?
Morningstar’s annual investment conference in Chicago last week was noticeably different than in years past. The 30th iteration focused less on stocks, funds, and other investments, and instead emphasized technology and tools to analyze them. The three-day gathering also served up big-picture thinking from luminaries such as veteran investor and environmental evangelist Jeremy Grantham, and Nobel Prize–winning behavioral psychologist Danny Kahneman.
- Zacks•6 days ago
Glaxo Two-Drug HIV Combo Meets Primary Endpoint in Phase III
Glaxo's (GSK) two late-stage studies testing its two-drug HIV regimen of dolutegravir (Tivicay) and lamivudine showed non-inferiority to a standard three-drug regimen
- Zacks•6 days ago
Dow 30 Stock Roundup: Caterpillar Raises Dividend, Merck's Keytruda Gets FDA Nod
The Dow traversed a tough week, suffering losses for three consecutive sessions.
- Zacks•6 days ago
Zacks Industry Outlook Highlights: Becton and Dickinson, Johnson & Johnson, Cigna and CVS Health
Zacks Industry Outlook Highlights: Becton and Dickinson, Johnson & Johnson, Cigna and CVS Health
- Simply Wall St.•6 days ago
Estimating The Fair Value Of Johnson & Johnson (NYSE:JNJ)
In this article I am going to calculate the intrinsic value of Johnson & Johnson (NYSE:JNJ) using the discounted cash flows (DCF) model. Anyone interested in learning a bit moreRead More...
- Zacks•6 days ago
Growth & Income Buys | Johnson & Johnson and International Paper
This week's video covers two companies where management has made key decisions for the future of their respective companies; Johnson & Johnson (JNJ), and International Paper (IP).
- CNBC•7 days ago
Kentucky sues Walgreens for its alleged role in the opioid crisis
Kentucky Attorney General Andy Beshear filed the suit against Walgreens for its dual role as a distributor and a pharmacy.
- Associated Press•7 days ago
Time Warner, Twenty-First Century Fox rise; H&R Block sinks
A federal judge cleared AT&T's $85 billion purchase of Time Warner in a major antitrust trial. The tax preparer said it is preparing price changes that will reduce its profit margins in the current fiscal year. The company said it is not in talks to buy medical device maker Boston Scientific.
- Reuters•7 days ago
Deals of the day-Mergers and acquisitions
** Comcast Corp offered $65 billion for Twenty-First Century Fox Inc media assets, emboldened by AT&T Inc prevailing over the Trump administration's attempt to block a merger with Time Warner Inc. ** AT&T Inc won court approval on Tuesday to buy Time Warner Inc for $85 billion, rebuffing an attempt by U.S. President Donald Trump's administration to block the deal and likely setting off a wave of corporate mergers.
